PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test powerful new drug cocktail to fight Fast-Growing lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, fast-growing B-cell lymphomas. The goal is to see if this combination is tolerable for patients and to gather initial data on its eff…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphomas: trial tests powerful drug combo
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called epcoritamab to a standard chemotherapy regimen (EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their s…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug could make revolutionary cancer treatment safer
Disease control Recruiting nowThis study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Fighting cancer with re-engineered immune cells: early trial seeks to tame tough lymphomas
Disease control Recruiting nowThis is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two powerful cancer treatments—CAR-T cell therapy and the drug pembrolizumab—works better than either alone for a type of lymphoma that has returned or not responded to prior treatments. About 35 adults with relapsed or refractory primary m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Cancer treatment may wipe out vaccine immunity, study investigates
Knowledge-focused Recruiting nowThis study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Mar 02, 2026 15:28 UTC